CORRECTION article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1656082
This article is part of the Research TopicBispecific Antibodies and their Conjugates in Solid Tumors and Hematological MalignanciesView all 7 articles
Correction: Bispecific Antibody for Lung Cancer: Mechanisms and Clinical Insights
Provisionally accepted
- 1West China Fourth Hospital Sichuan University, Chengdu, China
- 2Sichuan University, Chengdu, China
- 3West China Hospital of Sichuan University State Key Laboratory of Biotherapy, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Correction on: Chen W, Zhou A, Zhou Y. Bispecific antibody for lung cancer: mechanisms and clinical insights. Front Immunol. 2025 May 29;16:1572802. doi: 10.3389/fimmu.2025.1572802 Adding/removing text [State the error that was made]: The first sentence of the Introduction section contained erroneous data for the annual new lung cancer cases. The original text incorrectly stated "22 million new cases," which should be "2.2 million new cases" as cited in Reference 1.A correction has been made to the section "Introduction", Paragraph 1: Original incorrect paragraph: "Lung cancer is one of the world's most common cancers and the leading cause of cancer-related deaths, with an estimated 22 million new cases and 1.79 million deaths annually."Corrected paragraph: "Lung cancer is one of the world's most common cancers and the leading cause of cancer-related deaths, with an estimated 2.2 million new cases and 1.79 million deaths annually."The corrected data is derived from Reference 1 (DOI: 10.1016/S0140-6736(21)00312-3), which states: "With an estimated 2.2 million new cases and 1.79 million deaths per year, lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide."The original version of this article has been updated.
Keywords: bispecific antibodies, lung cancer, novel therapies, Immunotherapy, targeted therapy
Received: 29 Jun 2025; Accepted: 01 Jul 2025.
Copyright: © 2025 Chen, Zhou and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yunfeng Zhou, West China Fourth Hospital Sichuan University, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.